Aim Sequential therapies are essential to extend overall survival (OS) in patients with
unresectable hepatocellular carcinoma (HCC). Several second‐line treatments with …

Background: TGF-β signaling is associated with HCC progression in moderate to poorly
differentiated tumors. LY is a TGF-β receptor I kinase inhibitor currently in clinical testing in …

The pharmaceutical industry has entered challenging economic times, and some analysts
have questioned the longterm sustainability of its current business model [1]. The average …

Learning Objectives After completing this course, the reader will be able to: Describe the
currently recommended dose adjustments for common chemotherapeutics in oncology …

Purpose: The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism.
This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib …

Purpose The purpose of the current study is to analyze a series of phase I cancer clinical
trials, examine and compare trial protocols based on patients' eligibility criteria. Methods We …

Since the early trials in viral hepatitis, more and more new drugs are being tested for use in
various liver diseases. Since drug hepatotoxicity is a major cause of drugs under …

4581 Background: ABT-869 is a novel orally active, potent and selective inhibitor of the
vascular endothelial growth factor and platelet derived growth factor families of receptor …

Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended
phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D …

Simple Summary This review reports the risk and management of the hepatotoxicity of all the
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …